Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time

Rhea-AI Summary

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) and its partner MicroSafe Group announced that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for their product, Nanocyn^® Disinfectant and Sanitizer. This product kills common viruses, including SARS-CoV-2 and Norovirus, within 15 seconds, and common bacteria like MRSA and E. coli within 30 seconds. Nanocyn^® is non-toxic and certified for aircraft use. The company aims to expand its international distribution network while promoting its patented Microcyn^® Technology for various healthcare applications.

Positive

• Approval of extended claims for Nanocyn^® disinfectant by the TGA enhances product credibility.
• Nanocyn^® demonstrates a rapid kill time (15 seconds) for viruses and (30 seconds) for bacteria, increasing market appeal.
• Certification from major aviation manufacturers positions Nanocyn^® as a suitable disinfectant for aircraft, expanding its market potential.
• Sonoma Pharmaceuticals is actively seeking to expand its network of international distributors, indicating growth prospects.

Negative

• None.

WOODSTOCK, Ga.--(BUSINESS WIRE)-- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn^® Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma’s patented Microcyn^® Technology.

After original approval by the TGA and entry into The Australian Register Of Therapeutic Goods for use against SARS-CoV-2 (COVID 19) in mid-2020, the TGA has now approved extended claims for the hard-surface disinfectant Nanocyn^® with a 15 second kill time against common viruses, including SARS-CoV-2, Norovirus (Gastro), and influenza, and a 30-second kill contact time against common bacteria, such as Staphylococcus aureus (MRSA), E. coli, Pseudomonas aeruginosa, fungi and mold - including Candida Albicans.

“Nanocyn^® is a game-changer for any hospital, aged care or health care facility, transportation-provider, business, school, tourism or hospitality venue wanting to ensure their premises are COVID-safe, not just from a pandemic point of view, but also the comfort that comes with using a non-toxic disinfectant that does not leave any harmful residues behind,” said MicroSafe Group CEO Safa Qadumi.

In addition, Nanocyn^® had been previously certified by major aviation manufacturers. The product can disinfect aircraft without damaging sensitive materials. It is also the only TGA registered hospital grade disinfectant of its kind to be certified by Good Environmental Choice Australia (GECA).

Bruce Thornton, Chief Operating Officer of Sonoma Pharmaceuticals stated, “We could not be more excited about making our safe and effective Microcyn® Technology available to valued partners such as MicroSafe. We are continuously seeking to add to our network of international distributors to increase the reach of Sonoma products worldwide.”

About MicroSafe Group

The MicroSafe Group has operations in several international countries with its head office in Dubai, United Arab Emirates. With regional offices in the Middle East, as well as MicroSafe Care Australia and Canada, MicroSafe Group is providing innovative solutions to a wide range of industries and healthcare providers. The MicroSafe Group promotes only those products it believes will truly revolutionize healthcare – products that will enrich the lives of patients and healthcare professionals all over the world. Interested distributors for Europe, West Asia and North Africa may contact Safwan Abdallah, COO of MicroSafe Group at info@microsafecare.com. For Australia please contact MicroSafe Australia’s Managing Director Matt Seifert, at info@microsafe.com.au. More information can be found at www.microsafe.com and www.microsafe.com.au.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, dermatological conditions and disinfectant use. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211015005125/en/

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

ir@sonomapharma.com

 

Source: Sonoma Pharmaceuticals, Inc.

FAQ

What are the new claims approved for Sonoma Pharmaceuticals' Nanocyn^® product by the TGA?

The TGA approved extended claims for Nanocyn^® allowing it to kill common viruses, including SARS-CoV-2 and Norovirus, within 15 seconds, and common bacteria within 30 seconds.

How does Nanocyn^® benefit healthcare facilities?

Nanocyn^® is a non-toxic disinfectant effective against various pathogens, making it ideal for hospitals and healthcare facilities to ensure a safe environment.

What is the significance of the TGA approval for Sonoma Pharmaceuticals' stock performance?

The TGA approval boosts credibility and may enhance sales potential for Nanocyn^®, positively influencing investor sentiment for Sonoma Pharmaceuticals (SNOA).

Which viruses and bacteria does Nanocyn^® target?

Nanocyn^® targets viruses like SARS-CoV-2 and Norovirus, and bacteria including MRSA and E. coli, providing a broad spectrum of antimicrobial action.

What markets is Sonoma Pharmaceuticals looking to penetrate with Nanocyn^®?

Sonoma Pharmaceuticals is looking to expand its market reach internationally, especially in healthcare, aviation, and hospitality sectors.